scholarly journals Ischemic Stroke Risk Associated with Mitochondrial Haplogroup F in the Asian Population

Cells ◽  
2020 ◽  
Vol 9 (8) ◽  
pp. 1885
Author(s):  
Meng-Han Tsai ◽  
Chung-Wen Kuo ◽  
Tsu-Kung Lin ◽  
Chen-Jui Ho ◽  
Pei-Wen Wang ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Asian Population ◽  
Mitochondrial Haplogroup ◽  
Functional Differences ◽  
Mitochondrial Ros ◽  
Hypoxia Ischemia ◽  
History Of ◽  
Metalloproteinase 9 ◽  
Normal Controls

Mitochondrial dysfunction is involved in the pathogenesis of atherosclerosis, the primary risk factor for ischemic stroke. This study aims to explore the role of mitochondrial genomic variations in ischemic stroke, and to uncover the nuclear genes involved in this relationship. Eight hundred and thirty Taiwanese patients with a history of ischemic stroke and 966 normal controls were genotyped for their mitochondrial haplogroup (Mthapg). Cytoplasmic hybrid cells (cybrids) harboring different Mthapgs were used to observe functional differences under hypoxia-ischemia. RNA sequencing (RNASeq) was conducted to identify the particularly elevated mRNA. The patient study identified an association between Mthapg F1 and risk of ischemic stroke (OR 1.72:1.27–2.34, p = 0.001). The cellular study further demonstrated an impeded induction of hypoxic inducible factor 1α in the Mthapg F1 cybrid after hypoxia-ischemia. Additionally, the study demonstrated that Mthapg F cybrids were associated with an altered mitochondrial function, including decreased oxygen consumption, higher mitochondrial ROS production, and lower mitochondrial membrane potential. Mthapg F cybrids were also noted to be prone to inflammation, with increased expression of several inflammatory cytokines and elevated matrix metalloproteinase 9. The RNASeq identified significantly elevated expressions of angiopoietin-like 4 in Mthapg F1 cybrids after hypoxia-ischemia. Our study demonstrates an association between Mthapg F and susceptibility to ischemic stroke.

The Role of HbA1c on Mortality in Patients with Medical History of Ischemic Stroke and Paroxysmal Atrial Fibrillation

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2406-PUB
Author(s):  
KONSTANTINA KANELLOPOULOU ◽  
IOANNIS L. MATSOUKIS ◽  
ASIMINA GANOTOPOULOU ◽  
THEODORA ATHANASOPOULOU ◽  
CHRYSOULA TRIANTAFILLOPOULOU ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischemic Stroke ◽  
Medical History ◽  
Paroxysmal Atrial Fibrillation ◽  
History Of

scholarly journals Elevated IL-1α and CXCL10 Serum Levels Occur in Patients with Homozygous Sickle Cell Disease and a History of Acute Splenic Sequestration

2012 ◽  
Vol 32 (5) ◽  
pp. 295-300 ◽  
Author(s):  
Adel Driss ◽  
Nana O. Wilson ◽  
Karlene Mason ◽  
Hyacinth I. Hyacinth ◽  
Jacqueline M. Hibbert ◽  
...  
Keyword(s):  
Sickle Cell ◽  
Genetic Factors ◽  
Serum Levels ◽  
Control Group ◽  
Splenic Sequestration ◽  
Luminex Technology ◽  
History Of ◽  
Human Cytokines ◽  
Normal Controls

Acute splenic sequestration (ASS) and chronic hypersplenism are common features of homozygous sickle cell (SS) disease in the first 5 years of life affecting one-third of subjects in the Jamaican Cohort Study. The risk factors are largely unknown and the current study explores a possible role of genetic factors. We have explored these in subjects who received splenectomy in the management of ASS (n=8) or chronic hypersplenism (n=9) along with age, gender, and genotype matched controls using Luminex Technology to assess 42 human cytokines/chemokines, including IL-1α and CXCL10 (IP-10). Levels of IL-1α (p=0.008) and CXCL10 (p=0.009) were significantly elevated in patients treated by splenectomy compared with the control group. Levels of IL-1α were significantly higher in those with a history of ASS compared with matched normal controls (p=0.028) but not in those treated for hypersplenism (p=0.093). Furthermore, several significant differences were found in the median ratios of some cytokine biomarkers between the splenectomized group and the normal controls. These observations are consistent with acute splenic sequestration having a distinct phenotype which may be helpful in predicting those at risk of this complication and suggest that the mechanism of these differences merit further study.

Higher Risk of Ischemic Stroke Associated with Factor XI Levels in Dyslipidemic Patients.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3961-3961
Author(s):  
Maria Amparo Santamaria ◽  
Arturo Oliver ◽  
Jose Mateo ◽  
Roberto Belvis ◽  
Joan Marti-Fabregas ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Arterial Thrombosis ◽  
Complex Disease ◽  
Reference Group ◽  
Factor Xi ◽  
History Of ◽  
Low Levels ◽  
Genetic And Environmental Factors ◽  
Control Study

Abstract Ischemic stroke (IS) is a complex disease that involves genetic and environmental factors. The role of Factor XI in arterial thrombosis including IS is unclear. We have investigated the risk of IS related to Factor XI levels in a case-control study. We studied 445 individuals: 218 diagnosed with IS and 227 age-gender-ethnic control subjects. We measured Factor VIIIc, fibrinogen and Factor XIc levels. Factor XI<144% was taken as the reference group in the statistical analysis. Basic characteristic of patients and controls are summarized in the Table 1. When we analyzed the OR in all population, we observed an interaction between dyslipidemia and high FXI levels. So, we analyzed the data in 2 subgroups, dyslipidemic and non-dyslipidemic. The crude OR of IS in dyslipidemic patients with high levels of FXI was 4.2 (95% CI:1.2–14.8) compared with dyslipidemic controls and low levels of FXI, but the OR in the non-dyslipidemic with high levels of FXI subgroup was 1.2 (95% CI: 0.4–3.2). The adjusted OR of IS in dyslipidemic patients with high levels of FXI was 6.4 (95%CI: 1.6–26.1) compared with dyslipidemic controls, but the OR in non-dyslipidemic subgroup with high levels of FXI was 0.6 (95%CI: 0.2–2.1). In conclusion, we found almost a six-fold higher risk of IS in patients with dyslipidemia and high levels of FXI. Further studies should elucidate the role of Factor XI in IS and therapeutical approaches should become apparent in regard to patients with dyslipidemia and high Factor XI plasma levels. Table 1. IS (n=218)n (% ) Controls (n=227)n (% ) Unadjusted OR (95% CI) *Difference statistically significant (p<0.059 after adjustment by sex and age Sex (F/M) 104/114 108/119 NS Age (years, mean, range) 57 (23–80) 55(21–80) NS Smoking 94(45) 75(40) 1.6(1.1–2.3)* Dyslipidemia 91(42) 40(18) 3.4(2.2–5.2)* Family History of arterial thrombosis 112(51.7) 39(19) 5.1(3.3–7.8)* Hypertension 96(43.9) 39(17.3) 3.7(2.4–5.8)* Morbid Obesity 12(4.4) 6(2.6) 2.6(0.9–7.5) Alcohol Intake 20(9.2) 11(4.8) 1.9(0.9–4.2) Diabetes Mellitus 41(19) 12(5) 4.2(2.1–8.2)* Factor VIIIc(%, mean, range) 187.3(62–516) 157.1(48–360) p<0.0001 Fibrinogen (g/l)(mean, range) 3.7(1.9–8.4) 3.5(2.1–7.8) p<0.002

The role of HbA1c on mortality in patients with medical history of ischemic stroke and paroxysmal atrial fibrillation (pAfib)

2018 ◽  
Vol 275 ◽  
pp. e203
Author(s):  
K. Kanellopoulou ◽  
I.L. Matsoukis ◽  
T. Athanasopoulou ◽  
A. Ganotopoulou ◽  
N. Zimpounoumi ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischemic Stroke ◽  
Medical History ◽  
Paroxysmal Atrial Fibrillation ◽  
History Of

scholarly journals Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis

2017 ◽  
Vol 37 (9) ◽  
pp. 3253-3261 ◽  
Author(s):  
Anna Maria Gori ◽  
Betti Giusti ◽  
Benedetta Piccardi ◽  
Patrizia Nencini ◽  
Vanessa Palumbo ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Inflammatory Diseases ◽  
Brain Lesion ◽  
Hemorrhagic Transformation ◽  
Clinical Severity ◽  
Baseline Serum ◽  
History Of ◽  
Using Data ◽  
Poor Outcomes ◽  
Metalloproteinase 9

Inflammatory mediators and metalloproteinases are altered in acute ischemic stroke (AIS) and play a detrimental effect on clinical severity and hemorrhagic transformation of the ischemic brain lesion. Using data from the Italian multicenter observational MAGIC (MArker bioloGici nell’Ictus Cerebrale) Study, we evaluated the effect of inflammatory and metalloproteinases profiles on three-month functional outcome, hemorrhagic transformation and mortality in 327 patients with AIS treated with intravenous thrombolys in according to SITS-MOST (Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy) criteria. Circulating biomarkers were assessed at baseline and 24 h after thrombolysis. Adjusting for age, sex, baseline glycemia and National Institute of Health Stroke Scale, history of atrial fibrillation or congestive heart failure, and of inflammatory diseases or infections, baseline alpha-2macroglobulin (A2M), baseline serum amyloid protein (SAP) and pre-post tissue-plasminogen activator (tPA) variations (Δ) of metalloproteinase 9, remained significantly and independently associated with three-month death [OR (95% CI):A2M:2.99 (1.19–7.53); SAP:5.46 (1.64–18.74); Δmetalloproteinase 9:1.60 (1.12–2.27)]. The addition of baseline A2M and Δmetalloproteinase 9 or baseline SAP and Δmetalloproteinase 9 (model-2 or model-3) to clinical variables (model-1) significantly improved the area under curve for prediction of death [model-2 with A2M: p = 0.0205; model-3 with SAP: p = 0.001]. In conclusion, among AIS patients treated with thrombolysis, circulating A2M, SAP and Δmetalloproteinase 9 are independent markers of poor outcome. These results may prompt controlled clinical research about agents antagonizing their effect.

scholarly journals Relations between coagulation profiles, lipid profiles, and other risk factors with risk of first-ever ischemic stroke: a novel case-control study

Stroke ◽  
2001 ◽  
Vol 32 (suppl_1) ◽  
pp. 367-367
Author(s):  
Chyi-Huey Bai ◽  
Jiunn-Rong Chen ◽  
C. Kate Hsiao ◽  
Hou-Chang Chiu ◽  
Wen-Harn Pan
Keyword(s):  
Risk Factors ◽  
Ischemic Stroke ◽  
Carotid Plaque ◽  
Left Ventricular ◽  
Significance Level ◽  
Glucose Levels ◽  
Hemostatic Factors ◽  
History Of ◽  
Lipid Parameters

P156 Background and objectives: Several hemostatic factors and lipid parameters are associated with risk of coronary heart disease. Few studies have investigated the relations between these factors and risk of ischemic stroke. The major aim of this study was to estimate the risks of hypercoagulability, hyperlipidemia, hypertension, and hyperglycemia in acquiring first-ever ischemic stroke. An ancillary aim was to observe changes including biochemical and coagulation profiles in first-ever ischemic stroke inpatients from admission to 3 months later. Methods: One hundred and forty-four first-ever ischemic stroke inpatients and two types of controls (including 142 stable ischemic stroke outpatients and 181 non-stroke outpatients) were recruited from 1996 to 1999. Uric acid and glucose levels, status of hypertension, diabetes, left ventricular hypertrophy (LVH), and atrial fibrillation (AF), and coagulation (clotting times, fibrinogen, factor VIIc, and factor VIIIc) and lipid (cholesterol, triglyceride, HDL-C and LDL-C) profiles were obtained. Results: The proportions of cases with elevated fibrinogen and factor VIIIc from admission to 3 months later were significantly higher than those of non-stroke controls, either with or without anticoagulants. The proportions of cases with decreased HDL-C and hyperglycemia were also significantly higher than those of non-stroke controls. After adjusting for multiple cardiovascular risk factors, elevated fibrinogen (OR=3.21; p=0.0071), hyperglycemia (OR=2.65; p=0.0076), hypertension (OR=1.97; p=0.0424), history of LVH (OR=3.15; p=0.0010), and carotid plaque states (OR=2.27; p=0.0185) were significantly associated with risk of first-ever ischemic stroke. Elevated factor VIIIc was at borderline significance level (OR=2.12; p=0.0722). Conclusion: Hypertension, hyperglycemia, LVH and positive carotid plaque were associated with risk of first-ever ischemic stroke. Elevated fibrinogen and factor VIIIc were also associated with first-ever ischemic stroke, indicating a role of coagulation profiles in the pathogenesis of ischemic stroke.

Abstract TP347: Obstructive Sleep Apnea Frequency in Intracerebral Hemorrhage

Stroke ◽  
2020 ◽  
Vol 51 (Suppl_1) ◽  
Author(s):  
Jacqueline H Geer ◽  
Audrey C Leasure ◽  
Kevin N Vanent ◽  
Lauren H Sansing ◽  
Daniel Woo ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Ischemic Stroke ◽  
Sleep Apnea ◽  
High Risk ◽  
Intracerebral Hemorrhage ◽  
Berlin Questionnaire ◽  
Established Risk Factor ◽  
Obstructive Sleep ◽  
History Of

Introduction: Obstructive sleep apnea (OSA) is a treatable condition and well-established risk factor for ischemic stroke, but the prevalence in ICH is unknown. We aim to characterize the frequency of OSA in spontaneous intracerebral hemorrhage (ICH). Methods: The Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study is a prospective observational study evaluating risk factors for ICH among whites, blacks, and Hispanics. OSA status was determined using two different strategies: (1) the Berlin Questionnaire, a validated screening tool to identify those with a high likelihood of OSA where “high risk” is defined as > 1 point in at least 2 of 3 categories assessing snoring, fatigue, and hypertension, and (2) self-reported history of diagnosed sleep apnea. Results: We evaluated 3000 ICH cases. Within this group, 2896 (96.5%) completed the Berlin questionnaire, with 2064 (71%) patients being high risk for OSA. Compared to patients with low risk of OSA, those at high risk were more likely to be male (61% versus 53%, p<0.001) with hypertension (93% versus 65%, p<0.001), diabetes (32% versus 20%, p<0.001), hyperlipidemia (49% versus 38%, p<0.001), and higher BMI (29.8 +/- 8.1 versus 26.8 +/- 6.5, p<0.001), and less likely to have lobar ICH location (29% versus 35%, p<0.001). Self-reported history of prior sleep apnea diagnosis was present in only 175 (9.5%) of ICH cases. Conclusions: OSA is highly prevalent and underdiagnosed in our cohort of ICH patients. Given the effective treatments available for OSA, which have been shown to improve morbidity and mortality in patients with ischemic stroke, further studies are needed to assess the role of OSA as both a determinant of both risk and outcome in ICH.

scholarly journals Blood Biomarkers of Parenchymal Damage in Ischemic Stroke Patients Treated With Revascularization Therapies

2019 ◽  
Vol 14 ◽  
pp. 117727191988822 ◽  
Author(s):  
Benedetta Piccardi ◽  
Silvia Biagini ◽  
Veronica Iovene ◽  
Vanessa Palumbo
Keyword(s):  
Ischemic Stroke ◽  
Reperfusion Injury ◽  
Observational Studies ◽  
Hemorrhagic Transformation ◽  
Circulating Biomarkers ◽  
Stroke Patients ◽  
Capillary Dysfunction ◽  
Metalloproteinase 9 ◽  
Parenchymal Damage

Purpose: Postischemic reperfusion injury may exacerbate cerebral damage and capillary dysfunction, leading to brain edema (BE), hemorrhagic transformation (HT), necrosis, and injury from free radicals with subsequent infarct growth (IG). Several plasmatic biomarkers involved in the ischemic cascade have been studied in relation to radiological and clinical outcomes of reperfusion injury in ischemic stroke with heterogeneous results. This article provides a brief overview of the contribution of circulating biomarkers to the pathophysiology of parenchymal damage in ischemic stroke patients treated with revascularization therapies. Methods: We included full reports with measurements of plasma markers in patients with acute ischemic stroke treated with revascularization therapies. Findings: Our research included a large number of observational studies investigating a possible role of circulating biomarkers in the development of parenchymal damage after acute stroke treatments. To make the results clearer, we divided the review in 4 sections, exploring the relation of different biomarkers with each of the indicators of parenchymal damage (HT, BE, IG, recanalization). Discussion and conclusion: Definite conclusions are difficult to draw because of heterogeneity across studies. However, our review seems to confirm an association between some circulating biomarkers (particularly matrix metalloproteinase-9) and occurrence of parenchymal damage in ischemic stroke patients treated with revascularization therapies.

scholarly journals The History of Neurosurgical Management of Ischemic Stroke

2021 ◽  
Author(s):  
Lydia Kaoutzani ◽  
Scott Y. Rahimi
Keyword(s):  
Ischemic Stroke ◽  
Mechanical Thrombectomy ◽  
Meta Analysis ◽  
Public Health Issue ◽  
Symptomatic Carotid ◽  
The North ◽  
Intravenous Tissue Plasminogen Activator ◽  
History Of ◽  
Surgery Trial

Stroke remains a major public health issue and the second leading cause of death worldwide. The Hippocratic Corpus used the word apoplexy to describe a person collapsing while retaining pulse and respiration. This is believed to be the first written description of stroke. The theories of what caused stroke evolved over the years. When autopsies were performed stroke was attributed to emboli and thrombi formation. Carotid endarterectomies (CEA) were then performed for the treatment of stroke. Originally CEA were seen with skepticism but the North American Symptomatic Carotid Endarterectomy trial (NASCET) and the European Carotid Surgery trial (ECS) helped restore their efficacy in the management of ischemic stroke. A milestone in the management of ischemic stroke was the use of intravenous tissue plasminogen activator (tPA). Secondary to the limitations of the use of tPA other avenues were sought which included intraarterial recombinant prourokinase and mechanical thrombectomy. The field of mechanical thrombectomy continues to be rapidly changing and evolving. Various randomized controlled trials and meta-analysis have been conducted in order to evaluate who will benefit from mechanical thrombectomies, the timing, the best device to use and the role of combining this intervention with the administration of intravenous tPA.

Sign in / Sign up

Export Citation Format

Share Document